Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.69 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGFR | P43088 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11602008 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1FAAHTBXA2RPTGFR | |
| SCHEMBL11601264 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1FAAHTBXA2RPTGFR | |
| SCHEMBL11602010 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1FAAHTBXA2RPTGFR | |
| SCHEMBL11602477 | 0.90 | FFAR4 (0.71) | FFAR4FFAR1FAAHTBXA2RPTGFR | |
| SCHEMBL11601442 | 0.89 | FFAR4 (0.51) | FFAR4FFAR1FAAHGPR84MEN1 | |
| SCHEMBL11603394 | 0.86 | FFAR4 (0.65) | FFAR4FFAR1FAAHTBXA2RPTGFR | |
| SCHEMBL11602705 | 0.86 | FFAR4 (0.65) | FFAR4FFAR1FAAHTBXA2RPTGFR | |
| SCHEMBL11601867 | 0.86 | KDM4C (0.49) | FFAR4FFAR1 | |
| SCHEMBL11602265 | 0.86 | ACE2 (0.51) | FFAR4FFAR1FAAHGPR84 | |
| SCHEMBL11602268 | 0.85 | L3MBTL1 (0.52) | FFAR4FFAR1FAAHGPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951282-B1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER (US) | 2008-04-02 | — | — | EP | claimed |
| JP-2000507961-A | — | — | 2000-06-27 | — | — | JP | claimed |
| EP-0951282-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1998027976-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| US-4033996-A | RENAL VASODILATORS, ANTITHROMBOSIS, GROWTH HORMONE RELEASING | MERCK & CO., INC. (US) | 1977-07-05 | — | — | US | claimed |
| EP-0951282-B1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20020165255-A1 | Osteoporosis compounds | CAMERON KIMBERLY O (US) | 2002-11-07 | — | — | US | disclosed |
| US-6426359-B1 | THERAPY FOR BONE DISORDERS | PFIZER INC. | 2002-07-30 | — | — | US | disclosed |
| US-6376502-B1 | PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOPOROSIS. | PFIZER INC. | 2002-04-23 | — | — | US | disclosed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0951282-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998027976-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| US-4091107-A | RENAL VASODILATORS, ANTICLOTTING AGENTS, GROWTH HORMONE RELEASE, REGULATORS OF IMMUNE RESPONSE | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4033996-A | RENAL VASODILATORS, ANTITHROMBOSIS, GROWTH HORMONE RELEASING | MERCK & CO., INC. (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165255-A1 | Osteoporosis compounds | PTGER1, PTGIR, PTGER4 | FFAR4 171/4885FFAR1 180/4885FAAH 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.